Similar articles

• Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.

  Pfister C, Moore L, Allard P, Larue H, Lacombe L, Têtu B, Meyer F, Fradet Y. Pfister C, et al. Clin Cancer Res. 1999 Dec;5(12):4079-84. Clin Cancer Res. 1999. PMID: 10632343
• Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy.

  Zlotta AR, Noel JC, Fayt I, Drowart A, Van Vooren JP, Huygen K, Simon J, Schulman CC. Zlotta AR, et al. J Urol. 1999 Mar;161(3):792-8. J Urol. 1999. PMID: 10022686
• Expression of p53 and mdm2 and their significance in recurrence of superficial bladder cancer.

  Tuna B, Yörükoğlu K, Tüzel E, Güray M, Mungan U, Kirkali Z. Tuna B, et al. Pathol Res Pract. 2003;199(5):323-8. doi: 10.1078/0344-0338-00424. Pathol Res Pract. 2003. PMID: 12908522
• The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.

  Korkolopoulou P, Christodoulou P, Kapralos P, Exarchakos M, Bisbiroula A, Hadjiyannakis M, Georgountzos C, Thomas-Tsagli E. Korkolopoulou P, et al. Pathol Res Pract. 1997;193(11-12):767-75. doi: 10.1016/S0344-0338(97)80055-6. Pathol Res Pract. 1997. PMID: 9521509
• Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypes.

  Pfister C, Larue H, Moore L, Lacombe L, Veilleux C, Tetu B, Meyer F, Fradet Y. Pfister C, et al. Int J Cancer. 2000 Jan 20;89(1):100-4. Int J Cancer. 2000. PMID: 10719738